首页> 外国专利> Pharmaceutical dosage form entericamente coated extended release of an inhibitor of H +, K + - ATPase, Process for its manufactureUse of pharmaceutical dosage form of the inhibitor and use for preparing Medicine

Pharmaceutical dosage form entericamente coated extended release of an inhibitor of H +, K + - ATPase, Process for its manufactureUse of pharmaceutical dosage form of the inhibitor and use for preparing Medicine

机译:肠溶衣剂的药物剂型包衣的H +,K +-ATPase抑制剂的缓释剂,其制造方法抑制剂的药物剂型的用途和制备药物的用途

摘要

A long-term anesthetic release drug dose of H +, K + - atpas inhibitors, which provides long-term plasma separation of H +, K + - atpas inhibitors. The long-term characteristics in plasma are obtained by a drug synthesis method, including a kind of nucleon material in the water bottom or hydrofluorocarbon matrix, H +, K + - atpas inhibitors and optional drug front agents. H +, K + - atpas inhibitor is a formulated compound (I),Het1 is a formula (II);Het2 is formula (III);X = formula (IV),In reaction benzimidazol, n means that one of the cyclic carbon atoms substituted by r6-r9 can selectively exchange the denitorogeno atom without any substitutes; R1 R2 and R3 are the same or different, and are selected from hydrogen, tar and alcoxi, and can be replaced by fluorination, tar and alcoxix, Dichloromethane, pyridinediol, morphine, hydrogen halide, phenyl and phenylethanol; R4 and R5 are the same or different, and dehydrogenation, alkylation and arilalquilo are selected; R6 is hydrogen, halogenation, trifluoromethyl, tar or alcox; R6 and R9 are the same or different, and dehydrogeno, alcox, halogeno, halogeno, alcox, acarbonil are selected,Carbon oxide, oxazolinilo and trifluoroalkyl, or adjacent r6-r9 groups form deanillo structure which can be further replaced; R10 is a hydrogen structure, or forms an asphalt chain together with R3, R11 and R12; or different gypsum selected from hydrogen, halogenated hydrogen or aspha or an alkaline salt selected from it, One of its dwarfs or one of its alkali salts. It is better to select H +, K + - atpas inhibitors from the omeprazol group, omeprazol basic salts, deomprazal counterparts or (-) omeprazol counterparts or groups composed of lanzoprazol and pantoprazol.Alkaline salt, dwarfism, or alkaline salt. The underwater matrix is a kind of underwater polymer or a mixture of underwater polymers. Bottom matrix
机译:H +,K +-atpas抑制剂的长期麻醉释放剂量,可长期分离H +,K +-atpas抑制剂。血浆中的长期特性是通过药物合成方法获得的,包括水底或氢氟烃基质中的一种核子材料,H +,K +-atpas抑制剂和可选的药物前沿剂。 H +,K +-atpas抑制剂是配制的化合物(I),Het1是式(II); Het2是式(III); X =式(IV),在苯并咪唑的反应中,n表示环状碳原子之一被r6-r9取代的原子可以选择性地交换denitorogeno原子,而无需任何取代基; R1 R2和R3相同或不同,并且选自氢,焦油和醇盐,并且可以被氟化,焦油和醇盐,二氯甲烷,吡啶二醇,吗啡,卤化氢,苯基和苯乙醇取代; R4和R5相同或不同,并且选择脱氢,烷基化和芳基喹啉; R6是氢,卤代,三氟甲基,焦油或醇R6和R9相同或不同,并且选择脱氢,醇,卤代,卤代,醇,碳环,碳氧化物,恶唑啉基和三氟烷基,或相邻的r6-r9基团形成迪尼洛结构,可以进一步取代。 R10是氢结构,或与R3,R11和R12一起形成沥青链;或选自氢,卤化氢或沥青的不同石膏;或选自其中的碱金属盐,其矮人之一或碱金属盐之一。最好从奥美拉唑组,奥美拉唑碱式盐,去吡唑类或(-)奥美拉唑类或由兰索拉唑和潘托拉唑组成的组中选择H +,K +-atpas抑制剂,碱性盐,侏儒症或碱性盐。水下基质是一种水下聚合物或水下聚合物的混合物。底矩阵

著录项

  • 公开/公告号AR017201A1

    专利类型

  • 公开/公告日2001-08-22

    原文格式PDF

  • 申请/专利权人 ASTRAZENECA AB;

    申请/专利号AR1998P106244

  • 发明设计人

    申请日1998-12-09

  • 分类号A61K9/20;A61K9/22;A61K9/30;A61K31/44;A61K31/41;A61K31/425;A61K31/38;

  • 国家 AR

  • 入库时间 2022-08-22 01:26:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号